-
Listing
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Reglementen
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
-
Listing
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Reglementen
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
- Home
- About
- Media centre
- Bell en Gong Archief
- EnterNext welcomes Poxel on Euronext in Paris
EnterNext welcomes Poxel on Euronext in Paris
06/02/2015
Thomas Kuhn, CEO of Poxel, rings the opening bell.
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.
At the end of 2014, the group had 6 products including 1 in phase II of clinical development (Imeglimin), 1 in phase of preclinical development (PXL770) and 4 in research phase.